Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 1:2020:7692376.
doi: 10.1155/2020/7692376. eCollection 2020.

The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review

Eirini Palaka  1 , Susan Grandy  2 , Heleen van Haalen  3 , Phil McEwan  4 , Oliver Darlington  4
Affiliations

The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review

Eirini Palaka et al. Int J Nephrol. .

Abstract

Anaemia is a common consequence of chronic kidney disease (CKD); however, the risk factors for its development and its impact on outcomes have not been well synthesised. Therefore, we undertook a systematic review to fully characterise the risk factors associated with the presence of anaemia in patients with CKD and a contemporary synthesis of the risks of adverse outcomes in patients with CKD and anaemia. We searched MEDLINE, EMBASE, and the Cochrane Library from 2002 until 2018 for studies reporting the incidence or prevalence of anaemia and associated risk factors and/or associations between haemoglobin (Hb) or anaemia and mortality, major adverse cardiac events (MACE), hospitalisation, or CKD progression in adult patients with CKD. Extracted data were summarised as risk factors related to the incidence or prevalence of anaemia or the risk (hazard ratio (HR)) of outcome by Hb level (<10, 10-12, >12 g/dL) in patients not on dialysis and in those receiving dialysis. 191 studies met the predefined inclusion criteria. The risk factor most associated with the prevalence of anaemia was CKD stage, followed by age and sex. Mean HRs (95% CI) for all-cause mortality in patients with CKD on dialysis with Hb <10, 10-12, and >12 g/dL were 1.56 (1.43-1.71), 1.17 (1.09-1.26), and 0.91 (0.87-0.96), respectively. Similar patterns were observed for nondialysis patients and for the risks of hospitalisation, MACE, and CKD progression. This is the first known systematic review to quantify the risk of adverse clinical outcomes based on Hb level in patients with CKD. Anaemia was consistently associated with greater mortality, hospitalisation, MACE, and CKD progression in patients with CKD, and risk increased with anaemia severity. Effective treatments that not only treat the anaemia but also reduce the risk of adverse clinical outcomes are essential to help reduce the burden of anaemia and its management in CKD.

PubMed Disclaimer

Conflict of interest statement

EP, SG, and HvH are employees of AstraZeneca. PM and OD are employed by a company providing research and dissemination services to AstraZeneca and other pharmaceutical companies.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Risk factors associated with the presence of anaemia identified by more than one included study.
Figure 3
Figure 3
Associations between Hb level and mortality in CKD patients.
Figure 4
Figure 4
Associations between Hb level and hospitalisation, MACE, and CKD progression in CKD patients.
See this image and copyright information in PMC

References

    1. Jha V., Garcia-Garcia G., Iseki K., et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382(9888):260–272. doi: 10.1016/s0140-6736(13)60687-x. - DOI - PubMed
    1. Thomas R., Kanso A., Sedor J. R. Chronic kidney disease and its complications. Primary Care: Clinics in Office Practice. 2008;35(2):329–344. doi: 10.1016/j.pop.2008.01.008. - DOI - PMC - PubMed
    1. WHO. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Geneva, Switzerland: WHO; 2011. https://www.who.int/vmnis/indicators/haemoglobin.pdf.
    1. Babitt J. L., Lin H. Y. Mechanisms of anemia in CKD. Journal of the American Society of Nephrology. 2012;23(10):1631–1634. doi: 10.1681/asn.2011111078. - DOI - PMC - PubMed
    1. Malyszko J., Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney and Blood Pressure Research. 2007;30(1):15–30. doi: 10.1159/000098522. - DOI - PubMed

LinkOut - more resources